French Prime Minister Edith Cresson was forced last week by intense parliamentary opposition to postpone a vote on her government's proposed new drug agency until the spring.
One of the functions of the planned agency was to help bring French drug price-setting arrangements into line with the rest of the European Community. However, a move in the EC to set up a European-wide drugs agency - a project which has been widely welcomed by the European pharmaceutical industry - has also received a severe setback, after being on the agenda for some two years.
The agency is to function as the focus for the newly-harmonized drug marketing and other regulations in the single market. A few weeks ago, experts were predicting that members would adopt a "common position" on the agency issue.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze